Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment"

doi:10.1016/j.jri.2022.103639

Comment

. 2022 Aug:152:103639.

doi: 10.1016/j.jri.2022.103639. Epub 2022 May 10.

Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment"

Affiliations

¹ Clinical Pharmacology & Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; Teratology Information Service, Pharmacovigilance Centre Lareb, The Netherlands; L-C&Y, KU Leuven Child & Youth Institute, Belgium.
² Clinical Pharmacology & Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
³ Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.
⁴ Swiss Teratogen Information Service, Clinical Pharmacology Service, Lausanne University Hospital, Switzerland.
⁵ Materno-Fetal and Obstetrics Research Unit, Lausanne University Hospital, Switzerland; School of Health Sciences (HESAV), University of Applied Sciences and Arts Western Switzerland, Switzerland.
⁶ Rotunda Hospital, Ireland; School of Pharmacy, Royal College of Surgeons Ireland, Ireland.
⁷ Teratology Information Service, Pharmacovigilance Centre Lareb, The Netherlands.
⁸ UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
⁹ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway; Department of Child Health and Development, Norwegian Institute of Public Health, Norway.

PMID: 35569346
PMCID: PMC9088047
DOI: 10.1016/j.jri.2022.103639

Comment

Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment"

Michael Ceulemans et al. J Reprod Immunol. 2022 Aug.

. 2022 Aug:152:103639.

doi: 10.1016/j.jri.2022.103639. Epub 2022 May 10.

Authors

Affiliations

¹ Clinical Pharmacology & Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; Teratology Information Service, Pharmacovigilance Centre Lareb, The Netherlands; L-C&Y, KU Leuven Child & Youth Institute, Belgium.
² Clinical Pharmacology & Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
³ Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Switzerland.
⁴ Swiss Teratogen Information Service, Clinical Pharmacology Service, Lausanne University Hospital, Switzerland.
⁵ Materno-Fetal and Obstetrics Research Unit, Lausanne University Hospital, Switzerland; School of Health Sciences (HESAV), University of Applied Sciences and Arts Western Switzerland, Switzerland.
⁶ Rotunda Hospital, Ireland; School of Pharmacy, Royal College of Surgeons Ireland, Ireland.
⁷ Teratology Information Service, Pharmacovigilance Centre Lareb, The Netherlands.
⁸ UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
⁹ Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway; Department of Child Health and Development, Norwegian Institute of Public Health, Norway.

PMID: 35569346
PMCID: PMC9088047
DOI: 10.1016/j.jri.2022.103639

No abstract available

PubMed Disclaimer

Comment on

Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.
Vitiello A, Ferrara F, Zovi A, Trama U, Boccellino M. Vitiello A, et al. J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21. J Reprod Immunol. 2022. PMID: 35483212 Free PMC article. Review.

References

1. Antonucci R., Zaffanello M., Puxeddu E., Porcella A., Cuzzolin L., Pilloni M.D., Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr. Drug Metab. 2012;13(4):474–490. doi: 10.2174/138920012800166607. - DOI - PubMed
1. Ceulemans M., Foulon V., Panchaud A., Winterfeld U., Pomar L., Lambelet V., Cleary B., O’Shaughnessy F., Passier A., Richardson J.L., Nordeng H. Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. Int J. Environ. Res Public Health. 2022;19(3):1389. doi: 10.3390/ijerph19031389. - DOI - PMC - PubMed
1. Food Drug Administration, 2020, FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 〈https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-av....
1. Gerbier E., Favre G., Tauqeer F., Winterfeld U., Stojanov M., Oliver A., Passier A., Nordeng H., Pomar L., Baud D., Panchaud A., Meyer-Massetti C., Ceulemans M. Self-reported medication use among pregnant and postpartum women during the third wave of the COVID-19 pandemic: a European multinational cross-sectional study. Int J. Environ. Res Public Health. 2022;19(9) doi: 10.3390/ijerph19095335. - DOI - PMC - PubMed
1. Vitiello A., Ferrara F., Zovi A., Trama U., Boccellino M. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. J. Reprod. Immunol. 2022 doi: 10.1016/j.jri.2022.103630. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Antonucci R., Zaffanello M., Puxeddu E., Porcella A., Cuzzolin L., Pilloni M.D., Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr. Drug Metab. 2012;13(4):474–490. doi: 10.2174/138920012800166607. - DOI - PubMed

[2] Antonucci R., Zaffanello M., Puxeddu E., Porcella A., Cuzzolin L., Pilloni M.D., Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr. Drug Metab. 2012;13(4):474–490. doi: 10.2174/138920012800166607. - DOI - PubMed

[3] Ceulemans M., Foulon V., Panchaud A., Winterfeld U., Pomar L., Lambelet V., Cleary B., O’Shaughnessy F., Passier A., Richardson J.L., Nordeng H. Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. Int J. Environ. Res Public Health. 2022;19(3):1389. doi: 10.3390/ijerph19031389. - DOI - PMC - PubMed

[4] Ceulemans M., Foulon V., Panchaud A., Winterfeld U., Pomar L., Lambelet V., Cleary B., O’Shaughnessy F., Passier A., Richardson J.L., Nordeng H. Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries. Int J. Environ. Res Public Health. 2022;19(3):1389. doi: 10.3390/ijerph19031389. - DOI - PMC - PubMed

[5] Food Drug Administration, 2020, FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 〈https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-av....

[6] Food Drug Administration, 2020, FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 〈https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-av....

[7] Gerbier E., Favre G., Tauqeer F., Winterfeld U., Stojanov M., Oliver A., Passier A., Nordeng H., Pomar L., Baud D., Panchaud A., Meyer-Massetti C., Ceulemans M. Self-reported medication use among pregnant and postpartum women during the third wave of the COVID-19 pandemic: a European multinational cross-sectional study. Int J. Environ. Res Public Health. 2022;19(9) doi: 10.3390/ijerph19095335. - DOI - PMC - PubMed

[8] Gerbier E., Favre G., Tauqeer F., Winterfeld U., Stojanov M., Oliver A., Passier A., Nordeng H., Pomar L., Baud D., Panchaud A., Meyer-Massetti C., Ceulemans M. Self-reported medication use among pregnant and postpartum women during the third wave of the COVID-19 pandemic: a European multinational cross-sectional study. Int J. Environ. Res Public Health. 2022;19(9) doi: 10.3390/ijerph19095335. - DOI - PMC - PubMed

[9] Vitiello A., Ferrara F., Zovi A., Trama U., Boccellino M. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. J. Reprod. Immunol. 2022 doi: 10.1016/j.jri.2022.103630. - DOI - PMC - PubMed

[10] Vitiello A., Ferrara F., Zovi A., Trama U., Boccellino M. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. J. Reprod. Immunol. 2022 doi: 10.1016/j.jri.2022.103630. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment"

Affiliations

Comment to "Pregnancy and COVID-19, focus on vaccine and pharmacological treatment"

Authors

Affiliations

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical